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Perum Levels of Thiobarbituric Acid
eactive Substances Predict Cardiovascular
vents in Patients With Stable Coronary Artery Disease
Longitudinal Analysis of the PREVENT Study
ary F. Walter, PHD,* Robert F. Jacob, PHD,* Barrett Jeffers, PHD,‡ Mathieu M. Ghadanfar, MD,‡
regory M. Preston, PHD,§ Jan Buch, MD,‡ R. Preston Mason, PHD*†
everly and Boston, Massachusetts; New York, New York; and Groton, Connecticut
OBJECTIVES The objective of this study was to test the predictive value of an oxidative stress biomarker in
634 patients from the Prospective Randomized Evaluation of the Vascular Effects of Norvasc
Trial (PREVENT).
BACKGROUND Oxidative stress contributes to mechanisms of atherosclerosis and plaque instability. Biomar-
kers of oxidation, such as malondialdehyde (MDA), may represent independent indicators of
risk for patients with stable coronary artery disease (CAD).
METHODS Serum MDA levels were measured as thiobarbituric acid reactive substances (TBARS) in 634
patients with documented CAD using reverse-phase high-performance liquid chromatogra-
phy and spectrophotometric approaches.
RESULTS During the three-year study, there were 51 major vascular events such as fatal/nonfatal
myocardial infarction, 149 hospitalizations for nonfatal vascular events, and 139 patients
underwent a major vascular procedure. At baseline, patients with TBARS levels in the highest
quartile had a relative risk (RR) of 3.30 (95% confidence interval [CI] 1.47 to 7.42; p 
0.038) for major vascular events, RR of 4.10 (95% CI 2.55 to 6.60; p  0.0001) for nonfatal
vascular events, and RR of 3.84 (95% CI 2.56 to 5.76; p  0.0001) for major vascular
procedures. The effect of TBARS on events and procedures was also seen in a multivariate
model adjusted for inflammatory markers (C-reactive protein, soluble intercellular adhesion
molecule-1, interleukin-6), and other risk factors (age, low-density lipoprotein, high-density
lipoprotein, total cholesterol, triglycerides, body mass index, and blood pressure). This
analysis showed an independent effect of TBARS on major vascular events (p  0.0149),
nonfatal vascular events (p 0.0001), major vascular procedures (p 0.001), and all vascular
events and procedures (p  0.0001).
CONCLUSIONS Serum levels of TBARS were strongly predictive of cardiovascular events in patients with stable
CAD, independently of traditional risk factors and inflammatory markers. (J Am Coll Cardiol
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.08.0292004;44:1996–2002) © 2004 by the American College of Cardiology Foundation
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axidative modification of lipids associated with low-density
ipoprotein (LDL) and cellular constituents contributes to
echanisms of atherogenesis (1–3). It has been demon-
trated in previous studies that levels of malondialdehyde
MDA), often measured as thiobarbituric acid reactive
ubstances (TBARS), are elevated in association with car-
iovascular risk factors, such as cigarette smoking (4,5),
ypertension (6), hyperlipidemia (7,8), and diabetes (9,10).
hese findings indicate that there may be predictive value
or biomarkers of oxidation among patients with cardiovas-
ular disease, as compared with traditional risk factors.
The hypothesis of the current study is that elevated levels
f TBARS are associated with increased cardiovascular risk
n patients with stable coronary artery disease (CAD). This
ypothesis was tested using serum samples obtained from
From *Elucida Research, Beverly, Massachusetts; †Cardiovascular Division, De-
artment of Medicine, Brigham and Women’s Hospital, Harvard Medical School,
oston, Massachusetts; ‡Pfizer Inc., New York, New York; and §Pfizer Central
esearch, Groton, Connecticut. Funded by Pfizer Inc., New York, New York.
rs. Jeffers, Ghadanfar, Preston, and Buch are employees of Pfizer Inc.a
Manuscript received July 9, 2004; revised manuscript received August 3, 2004,
ccepted August 10, 2004.he Prospective Randomized Evaluation of the Vascular
ffects of Norvasc Trial (PREVENT), a prospective,
ouble-masked clinical trial. Patients in this study had
ocumented coronary disease and were treated with either
mlodipine or placebo. Treatment with amlodipine was
ssociated with significantly fewer cases of unstable angina
nd coronary revascularization without a reduction in lumi-
al loss (11). This benefit with amlodipine may be attrib-
ted to various mechanisms, as previously reviewed (12).
or the biomarker analysis, serum samples were collected
rom 634 patients at baseline and at the end of each
2-month period during the 3-year study. The level of the
DA-thiobarbituric-acid complex was precisely measured
fter separation by reverse-phase high-performance liquid
hromatography coupled with spectrophotometric and flu-
rescence detection (13,14). The association of TBARS
ith clinical events and procedures was evaluated in univar-
ate and multivariate models adjusting for inflammatory
arkers (C-reactive protein [CRP], soluble intercellular
dhesion molecule-1 [sICAM-1], interleukin-6 [IL-6]),
nd other risk factors (age, gender, lipids, body mass index,
nd blood pressure).
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eneral design features. PREVENT was a multicenter,
andomized, placebo-controlled, double-masked clinical
rial of patients who had angiographic evidence of CAD
11). Men and women (30 to 80 years old) were randomized
f there was angiographic evidence of one focal coronary
esion of 30% diameter stenosis (non-intervened and
on-infarcted) and the presence of 1 lesion with a 5% to
0% stenosis that was not in a vessel with a 60% lesion.
ther eligibility criteria included diastolic blood pressure of
95 mm Hg, total cholesterol of 325 mg/dl, and fasting
lood glucose of 200 mg/dl. Randomization was stratified
ccording to clinical center and history of percutaneous
ransluminal coronary angioplasty (PTCA).
onitoring for clinical events and adverse experiences. The
respecified clinical events were all-cause mortality and the
ccurrence of major fatal/nonfatal vascular events or proce-
ures. Death, myocardial infarction, stroke, hospitalized
eart failure, and hospitalized episodes of unstable angina
ere classified by an external events classification committee
linded to treatment assignment. Confirmation of unstable
ngina required hospitalization for typical chest pain and
ither evidence of myocardial ischemia (electrocardiogram
r stress test evidence, or new angiographic findings of
isease) or an indication that this pain was similar to that of
reviously documented evidence of ischemia.
ngiographic methods and outcomes. The progression of
arly atherosclerotic segments was determined on the basis
f a change in mean minimal diameter with quantitative
oronary angiography (QCA) (15,16). Atherosclerotic seg-
ents were defined as coronary segments with a diameter
tenosis of 30% at baseline. Up to 12 coronary segments
ere used in the analysis of disease progression (17). Vessels
hat underwent a procedure at or before baseline were
xcluded from the analyses. The baseline and follow-up
lms were centrally read pairwise by a certified reader who
as blinded to treatment assignment and the temporal
Abbreviations and Acronyms
CABG  coronary artery bypass grafting
CAD  coronary artery disease
CI  confidence interval
CRP  C-reactive protein
HDL  high-density lipoprotein
IL-6  interleukin-6
LDL  low-density lipoprotein
MDA  malondialdehyde
PTCA  percutaneous transluminal coronary
angioplasty
PREVENT  Prospective Randomized Evaluation of the
Vascular Effects of Norvasc Trial
QCA  quantitative coronary angiography
RR  relative risk
sICAM-1  soluble intercellular adhesion molecule-1
TBARS  thiobarbituric acid reactive substancesequencing of films. leasurement of serum TBARS levels. Serum samples
ere obtained from 634 fasting participants at the begin-
ing of the study (baseline) and at the end of each of the
hree years. Samples were stored at 70°C without the
ddition of exogenous antioxidants before TBARS analysis.
fter thawing the samples, measurements of MDA in terms
f TBARS were performed in duplicate in each of 2,975
amples by the method of Carbonneau et al. (18) with slight
odifications. Briefly, 50 l of 10 M sodium hydroxide
NaOH) was added to 0.5 ml of serum and incubated at
0°C for 30 min. The sample was then acidified to pH 1.0
ith 500 l of 586 g/l perchloric acid. After centrifugation,
00 l of supernatant was added to 50 l of thiobarbituric
cid or TBA (10 g/l in 50 mM phosphate buffer, pH 7.0)
nd heated at 100°C for 30 min. The sample was cooled and
00 l removed for high-performance liquid chromatogra-
hy analysis. The MDA that reacts with TBA in this
eaction is generated from lipid hydroperoxides and poten-
ially other biologic sources (e.g., glucose).
The MDA-thiobarbituric-acid complex was separated
rom other possible reactants with TBA using reverse-phase
igh-performance liquid chromatography on a Varian Pros-
ar system (Varian Inc., Walnut Creek, California) coupled
ith a spectrophotometric detector at 532 nm and a
uorescence detector (excitation 515 nm, emission 553
m) on a 150 mm  4.6 mm Adsorbosphere (Alltech
ssociates Inc., Deerfield, Illinois) C18 column with 5 m
article size. The purpose for using reverse-phase high-
erformance liquid chromatography followed by quantita-
ion with both spectrophotometry and fluorescence was to
liminate other aldehydes that react with TBA and have
bsorbance characteristics at 532 nm (13,14,19). The flow
ate was 1 ml/min, and the mobile phase was 80% phos-
hate buffer (10 mM, pH 5.8) with 20% methanol. A
tandard curve was run at the start, middle, and end of each
ample set using 1,1,3,3-tetraethoxypropane as a standard.
eak areas were determined using the Star Chromatography
orkstation (Varian Inc.).
easurement of serum CRP, IL-6, and sICAM-1. C-
eactive protein levels were measured using the N Latex
RP mono assay (Dade Behring Inc., Deerfield, Illinois)
ith a detection limit of 0.21 mg/l. Samples with values
elow the limit of detection were recorded as 0.21 mg/l;
he value 0.20 mg/l was incorporated for statistical analyses.
ntra- and interassay precision for the low quality control
QC) (0.46 mg/l) had coefficient of variations (CVs) of
.9% and 14.8%, respectively. Serum soluble intercellular
dhesion molecule-1 levels were measured with the Param-
ter Human sICAM-1 Immunoassay Kit (R&D Systems,
inneapolis, Minnesota), with a range of 0 to 588 ng/ml.
ntra- and interassay precision for the middle QC (282.7
g/ml) had CVs of 9.0% and 9.5%, respectively.
nterleukin-6 levels were measured using the Quantikine
S IL-6 R&D Systems kit, which had an assay range of
.156 to 10 pg/ml. Intra- and interassay precision for the
ow QC (0.338 pg/ml) had CVs of 9.9% and 14.4%,
r
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TBARS Levels and Cardiovascular Risk November 16, 2004:1996–2002espectively. All measurements were made by Esoterix
oagulation (Aurora, Colorado).
tatistical analysis. Simple descriptive statistics were used
o describe the population. For clinical outcomes, propor-
ional hazards regression models were used to obtain haz-
rds ratios and associated 95% confidence intervals (CI).
he first proportional hazards model used baseline TBARS
nd treatment as covariates for each clinical outcome (major
ascular events, hospitalizations for angina, coronary artery
ypass grafting [CABG], PTCA, and major vascular pro-
edures). Finally, to further investigate the impact of
BARS on clinical outcomes, a proportional hazards model
as performed using quartiles of baseline TBARS with the
eference group being those in the lowest quartile.
Pearson’s correlation coefficients were used to assess the
orrelation between TBARS and coronary angiography
utcomes measurements (e.g., all segments, segments ste-
osed 30%, segments stenosed 30% and 50%, and
egments stenosed 50%) as well as TBARS and changes
able 1. PREVENT: Baseline Description of Patients (n  634)
Mean*
ariable
Age (yrs) 57.2 9.6
Male (%) 80.9
Female (%) 19.1
Total cholesterol (mg/dl) 217.9  39.1
HDL cholesterol (mg/dl) 45.7  11.5
LDL cholesterol (mg/dl) 132.4  36.1
Triglycerides (mg/dl) 203.7  131.7
Average systolic BP (mm Hg) 129.0  17.4
Average diastolic BP (mm Hg) 78.6 9.1
Body mass index (kg/m2) 27.9  4.6
Current smoker (%) 24.9
Past smoker (%) 54.9
Prior MI (%) 47.3
Prior angina (%) 51.6
edication use
Calcium channel blocker (%) 33.8
ACE inhibitor (%) 9.1
Diuretic (%) 11.8
Beta-blocker (%) 62.8
Nitrates (%) 63.8
Lipid-lowering agent (%) 27.3
Values are mean  SD unless indicated otherwise.
ACE  angiotensin-converting enzyme; BP  blood pressure; HDL  high-
ensity lipoprotein; LDL  low-density lipoprotein; MI  myocardial infarction;
REVENT  Prospective Randomized Evaluation of the Vascular Effects on
orvasc trial.
Table 2. PREVENT: Predictive Value of TBA
CV Event
Major vascular events, (fatal/nonfatal MI, stroke)
Hospitalizations for angina
CABG
PTCA
Major vascular procedures, (CABG/PTCA)
*per 1.0 mol/l.
CABG  coronary artery bypass grafting; CI  confidenc
angioplasty; RR  relative risk; TBARS  thiobarbituric acid rean patient characteristics (e.g., change in systolic blood
ressure, change in diastolic blood pressure, change in
igh-density lipoprotein [HDL], change in LDL, and
hange in triglycerides). All analyses were undertaken using
lpha  0.05 and were performed using SAS Version 8.2
SAS Institute Inc., Cary, North Carolina).
ESULTS
he baseline patient characteristics of the study cohort are
hown in Table 1.
linical events. During the study, there were 51 major
ascular events such as fatal/nonfatal myocardial infarction
nd stroke; 149 hospitalizations for nonfatal cardiovascular
vents (mainly unstable angina); 139 patients also under-
ent a major vascular procedure, such as PTCA/CABG.
BARS levels and clinical events. Table 2 shows the
elationship between measured baseline levels of TBARS
nd cardiovascular events in PREVENT. At baseline, the
verall mean absolute level of TBARS was 1.49 0.57 M.
aseline levels of TBARS were associated with risk for
atal/nonfatal myocardial infarction with a relative risk (RR)
f 2.94 (95% CI 1.75 to 4.94), an RR of 2.58 (95% CI 1.98
o 3.37) for nonfatal cardiovascular events, and an RR of
.14 for nonfatal vascular events (95% CI 1.61 to 2.84). The
bsolute levels of TBARS in patients with and without
pecific vascular events and procedures events were reviewed
n Table 3. The significant univariate effect of TBARS seen
n major vascular events, nonfatal vascular events, vascular
rocedure, and all vascular events and procedures is also seen
n a multivariate model adjusting for inflammatory markers
nd known cardiovascular risk factors. Specifically, a multi-
ariate Cox proportional hazards regression model was
ndertaken where the following variables were included in
he analysis: TBARS, inflammatory markers (sICAM-1,
L-6, CRP), age, gender, total cholesterol, HDL, LDL,
riglycerides, systolic blood pressure, diastolic blood pres-
ure, and body mass index. After adjusting for all of these
ariables, TBARS levels showed an independent effect on
ajor vascular events (p  0.0149), nonfatal vascular events
p  0.0001), vascular procedure (p  0.001), and all
ascular events and procedures (p  0.0001).
We measured levels of inflammatory markers at baseline.
he median (25th/75th percentile) levels at baseline for
L-6, sICAM-1, and hs-CRP were 2.7 pg/ml (1.7, 4.3), 2.1
Serum Levels (Baseline)
umber
th Event RR* 95% CI for RR p Value
51 2.94 1.75–4.94 0.0001
149 2.58 1.98–3.37 0.0001
46 2.32 1.43–3.77 0.0007
93 2.21 1.59–3.06 0.0001
139 2.14 1.61–2.84 0.0001RS
N
Wie interval; PTCA  percutaneous transluminal coronary
ctive substances. Other abbreviations as in Table 1.
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November 16, 2004:1996–2002 TBARS Levels and Cardiovascular Riskg/ml (1.7, 2.5), and 2.5 mg/l (1.2, 5.5), respectively. A
ignificant correlation of TBARS with levels of IL-6 (p 
.0001) was observed (correlation coefficient of 0.148).
owever, baseline levels of TBARS did not correlate with
ither CRP, an acute phase reactant (p  0.722), or
ICAM-1 (p  0.052).
In Figure 1, it is demonstrated that participants with the
ighest baseline TBARS levels were at increased risk for
xperiencing a major vascular event (RR of 3.30; 95% CI
.47 to 7.42), nonfatal cardiovascular event (RR of 4.10;
5% CI 2.55 to 6.60), major vascular procedure (RR of 3.29;
5% CI 2.09 to 5.15), and all vascular events and procedures
RR of 3.84; 95% CI 2.56 to 5.78). Additionally, patients in
he highest quartile had an increased risk of fatal/nonfatal
I (RR of 5.07; 95% CI 1.70 to 15.06; p  0.0035),
eveloping angina (RR of 4.03; 95% CI 2.50 to 6.49; p 
.0001), undergoing a CABG procedure (RR of 3.03; 95%
I 1.33 to 6.88; p  0.0080) or PTCA (RR of 3.12; 95%
I 1.74 to 5.58; p  0.0001), and experiencing a fatal/
onfatal myocardial infarction (RR of 5.07; 95% CI 1.70 to
5.06; p  0.0035).
In PREVENT, treatment with amlodipine was associ-
ted with a 31% reduction in the RR of a major/
ocumented vascular event or procedure (p  0.01). How-
ver, changes in levels of TBARS during the three-year
eriod were not significantly different in patients on amlo-
ipine versus placebo (n  596; p  0.336).
The mean absolute levels of TBARS were stable over the
hree-year period due to uniformity in the handling and
torage of the samples. The mean absolute levels were 1.5
.6 M, 1.4  0.3 M, 1.3  0.4 M, and 1.3  0.4 M
t baseline, month 12, month 24, and month 36, respec-
ively. By contrast, the absolute mean levels of TBARS in
he highest quartiles were in the range of 3.3 to 4.1 M,
epending on the cardiovascular event category.
BARS levels and angiographic measurements. Changes
n TBARS over the three-year study correlated poorly with
ngiographic outcome measurements. In all segments eval-
ated, there was a significant association (n  515; p 
.021) between angiographic determinations of lesion de-
elopment and serum TBARS levels, but the correlation
oefficient was 0.100. In particular, changes in TBARS
Table 3. PREVENT: Comparative Mean Abs
Vascular Events and Procedures
CV Event
Ev
M
Major vascular events (MI, stroke) 1.
Fatal/nonfatal MI 1.
Nonfatal vascular events (angina/CHF) 1.
Angina 1.
Major vascular procedures (CABG/PTCA) 1.
All vascular events and procedures 1.
*Malondialdehyde levels for patients with vs. without events
CHF  congestive heart failure. Other abbreviations asevels correlated with progression of moderate coronary
P
rtenoses (30% and 50%) in a significant fashion (n 
74; p  0.024) with a correlation coefficient of 0.105, but
ot in minimal segments of 30% (n  507; p  0.085) or
arger segments of 50% (n  237; p  0.742). The p
alues were calculated from the Spearman rank correlation
oefficient.
BARS levels and patient characteristics. Thiobarbituric
cid reactive substances chromatography levels were
trongly associated with a higher risk of cardiovascular
orbidity, independently of other known risk factors, such
s blood pressure (systolic and diastolic) or lipids (HDL,
igure 1. Quartile analysis of a lipid oxidation marker (malondialdehyde
easured as thiobarbituric acid reactive substances) in patients with
ocumented coronary artery disease. CABG  coronary artery bypass
rafting; CHF  congestive heart failure; MI  myocardial infarction;
TBARS Serum Levels With Specific
ts With
Procedures
Patients Without
Events/Procedures
p Value*SD Mean SD
0.609 1.466 0.556 0.001
0.556 1.468 0.556 0.001
0.633 1.423 0.529 0.001
0.638 1.424 0.528 0.001
0.630 1.436 0.537 0.001
0.625 1.400 0.516 0.001
dures (two-sample t test).
les 1 and 2.olute
Patien
ents/
ean
836
944
760
765
729
743TCA  percutaneous transluminal coronary angioplasty; RR  relative
isk.
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TBARS Levels and Cardiovascular Risk November 16, 2004:1996–2002DL, and triglycerides). Levels of TBARS also did not
orrelate with baseline demographics such as gender, history
f smoking, previous angina, or a family history of myocar-
ial infarction or sudden death. However, a patient’s history
f a myocardial infarction correlated significantly with
aseline TBARS levels (n  659; p  0.035). The level of
BARS was 1.54  0.61 M (n  309) for patients who
ad a history of a myocardial infarction, whereas the level
as 1.45  0.52 M (n  350) for patients without such a
revious event.
ISCUSSION
he essential finding from this study was that measured
evels of a lipid oxidation marker (MDA measured as
BARS) were strongly associated with cardiovascular
vents in the PREVENT study, including fatal/nonfatal
yocardial infarction and stroke, hospitalizations for non-
atal cardiovascular events (mainly unstable angina), and
ajor vascular procedures, such as PTCA/CABG. Thio-
arbituric acid reactive substances chromatography levels
easured during the study period were predictive of cardio-
ascular events independently of blood pressure (systolic and
iastolic), lipids (total cholesterol, HDL, LDL, and triglyc-
rides), inflammatory markers (sICAM-1, IL-6, CRP), age,
ender, and body mass index. A weak but significant
orrelation was also observed between levels of TBARS and
ngiographic progression of disease, especially moderate
oronary stenoses (30% and 50%). Although amlodip-
ne treatment was associated with significantly fewer car-
iovascular events, it did not influence TBARS levels.
To our knowledge, this is the first longitudinal study
emonstrating an association between elevated TBARS in
erum and cardiovascular risk in patients with stable CAD.
revious studies in relatively small populations had demon-
trated correlations between levels of TBARS and key
ardiovascular risk factors, including cigarette smoking,
ypertension, hyperlipidemia, and diabetes (5,6). Markers
f lipid peroxidation, including LDL oxidation, have also
een associated with the development of coronary disease
20–24). In one study of 206 subjects, TBARS levels
orrelated with severity of disease as determined by angiog-
aphy, independently of other known risk factors (total
holesterol, LDL, triglycerides) (21). In another small study
f 29 patients with coronary disease, use of lipid-lowering
gents (HMG-CoA reductase inhibitor, bile sequestrant)
as associated with significantly lower levels of serum
BARS in a manner that correlated strongly with endothe-
ial function (25). Collectively, these studies support an
merging role for markers of oxidative stress in the predic-
ion of risk for cardiovascular disease.
In this study, the serum levels of TBARS measured at
aseline in these patients correlated directly with levels of
he proinflammatory cytokine, IL-6. Production of IL-6
rom vascular cells is triggered by the proatherogenic factor,
ngiotensin II (26), which also stimulates reactive oxygen ipecies involved in LDL oxidation. Cytokine production
rom smooth muscle cells is also stimulated directly by
xidized LDL (27). Given the interrelationships between
ytokine expression, angiotensin II, and reactive oxygen
pecies, the correlation between levels of this cytokine and
BARS may result from common early events in athero-
enesis. Elevations in IL-6, in turn, lead to increased release
f the acute phase reactant CRP from the liver (28), an
nflammatory marker that predicts cardiovascular risk (29).
he lack of an association between levels of TBARS and
RP is not well understood but may indicate only an
ndirect relationship between the expression of certain
nflammatory markers and markers of advanced oxidative
amage in these patients with stable CAD.
Oxidative modification of lipids associated with LDL and
ellular constituents contribute to endothelial dysfunction
nd inflammatory pathways associated with atherosclerosis
1–3,30,31). The mechanism of in vivo LDL oxidation is
ot fully understood, but results of mass spectroscopy
nalyses indicate elevated levels of protein oxidation prod-
cts in human atherosclerotic lesions that may be attributed
o myeloperoxidase activity (32). Besides measurements of
BARS, other approaches have been used to assess
xidative stress levels, such as monoclonal antibodies
gainst oxidized LDL, protein oxidation markers, and
easurement of isoprostanes (33–35). Isoprostanes are
rostaglandin-like compounds that may be formed in vivo
rom the free-radical-initiated peroxidation of arachidonic
cid, independently of the cyclooxygenase pathway. Studies
ave demonstrated that these compounds are found in the
laque and associated with increased risk for cardiovascular
isease (36,37). In vivo oxidative stress levels have been
uantitated by several different methods (33,38,39).
tudy limitations. A limitation of this study was that the
DA measured in the TBARS assay may be generated, in
ome part, from sources other than lipid hydroperoxides
ssociated with lipoproteins, such as glucose, bilirubin, and
mino acids. Additionally, measurements were carried out
ith serum samples from patients, the preparation of which
ould theoretically lead to some MDA development. Fi-
ally, preservatives (e.g., antioxidants) were not added to the
erum samples as part of the storage procedure at 70°C,
nd this could contribute to MDA formation over time. It
hould be noted, however, that the absolute mean levels of
DA were stable over the course of the three-year study.
mplications for antioxidant treatment. The implication
f these data for the role of antioxidants in the treatment of
AD is an interesting question. Although epidemiologic
nd laboratory animal studies indicate that low levels of
ntioxidants are associated with increased risk for cardio-
ascular disease, the results of large prospective antioxidant
linical trials have failed to show a benefit, as recently
eviewed (40,41). Possible explanations for this paradox may
e due to trial design, baseline antioxidant status of partic-
pants, dosage and source of the antioxidants, and time of
ntervention relative to disease progression. An additional
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2001JACC Vol. 44, No. 10, 2004 Walter et al.
November 16, 2004:1996–2002 TBARS Levels and Cardiovascular Riskxplanation is that vitamin E does not neutralize relevant
xidants, such as those produced by myeloperoxidase (42),
nd/or there is reduced penetration of this natural antioxi-
ant into the atherosclerotic plaque. This latter concept was
valuated in patients with advanced atherosclerosis after
itamin E supplementation (450 IU/day). This analysis
howed that, despite a reduction in plasma markers of
xidation with vitamin E, there was no change in vitamin E
ontent or levels of oxysterols in the plaque itself (43). This
ay be due to the effects of hyperlipidemia on the choles-
erol content on vascular cell plasma membranes (44). This
ncrease in membrane cholesterol content interferes with the
bility of lipophilic molecules to partition into the lipid
nvironment, as we have previously demonstrated with
ardiovascular agents (45). Thus, vessel wall changes in
atients with advanced atherosclerosis may attenuate the
bility of tocopherol to partition into plaque and scavenge
ree radicals. Synthetic antioxidants with superior scaveng-
ng activity and lipophilic properties may have different
ffects on oxidative stress markers in the plaque and bene-
cially influence the course of the disease.
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